ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Biocatalyst developer Codexis has licensed its enzyme engineering technology to GlaxoSmithKline for making pharmaceuticals and other health care products. GSK will pay Codexis $6 million up front and another $19 million over two years as it transfers the technology to its Upper Merion, Pa., R&D site. Under the license, GSK can use the technology to develop enzymes for manufacturing processes and to create therapeutic, diagnostic, and prophylactic products. Codexis could receive milestone payments of up to $39 million per project, plus royalties, if GSK is successful in using the technology.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X